Result: Mutation Q148H, the most frequently observed in HIV-1 at this position, was not present in our dataset.
Discussion: Mutation Q148H, the most frequently observed in HIV-1 at this residue was not detected in our dataset.
Comparative replication capacity of raltegravir-resistant strains and antiviral activity of the new-generation integrase inhibitor dolutegravir in human primary macrophages and lymphocytes.
PMID: 24860155
2014
The Journal of antimicrobial chemotherapy
Abstract: In C8166 (the only cell model in which replication capacity was sufficient to perform the test) dolutegravir showed full efficacy against mutations N155H + Y143C (dolutegravir fold-change resistance: 0.6) and a slightly lower activity against G140S+Q148H (dolutegravir fold-change resistance: 2.1).
Abstract: In MDMs and PBMCs, a dramatic decrease in viral replication was observed for the double mutants N155H + Y143C and G140S + Q148H (ranging from 0.1% to 2.5% compared with wild-type).
Abstract: The following raltegravir resistance mutations were analysed: N155H, Y143C, N155H + PMID: 24899199
2014
Journal of virology
Abstract: Conversely, RT-E138K and -Y181C mutations improved the fitness of the IN-G140S/Q148H mutant virus in the presence of raltegravir (RAL); the RT-K103N mutation had no effect.
Abstract: However, both the RT-K103N plus IN-G140S/Q148H and the RT-E138K plus IN-G140S/Q148H mutant viruses had significantly greater fold increases in 50% inhibitory concentrati
2014 Update of the drug resistance mutations in HIV-1.
Discussion: N155H mutants tend to predominate early in th
Discussion: Cross-resistance studies with raltegravir- and elvitegravir-resistant viruses indicate that Q148H and G140S in combination with mutations L74I/M, E92Q, T97A, E138A/K, G140A, or N155H are associated with 5-fold to 20-fold reduced dolutegravir susceptibility and reduced virologic suppression in patients.
Discussion: Minor mutations described in the Q148H/K/R pathway include L74M plus E138A, E138K, or G140S.
Molecular dynamics simulation studies of the wild type and E92Q/N155H mutant of Elvitegravir-resistance HIV-1 integrase.
PMID: 25373632
2014
Interdisciplinary sciences, computational life sciences
Abstract: Although Elvitegravir (EVG) is a newly developed antiretrovirals drug to treat the acquired immunodeficiency syndrome (AIDS), drug resistance has already been found in clinic, such as E92Q/N155H and Q148H/G140S.
Longitudinal analysis of integrase N155H variants in heavily treated patients failing raltegravir-based regimens.
Abstract: During RAL failure, the mutation N155H was detected at different levels in three patients displaying the N155H pathway and gradually declined when the double mutant Q148H+G140S was selected in one patient.
Abstract: In two patients with the Q148H resistance pathway, no N155H variant was identified by AS-PCR in either viral RNA or DNA.
Activities, crystal structures, and molecular dynamics of dihydro-1H-isoindole derivatives, inhibitors of HIV-1 integrase.
Introduction: Using a panel of recombinant INs that carry the Y143R, N155H and G140S-Q148H mutations, we reported that elvitegravir (EVG, Gilead Sciences), dolutegravir (DTG, ViiV Healthcare/Shionogi) and MK-0536 (Merck & Co.) retain high efficacy against these RAL-resistant mutants.
Result: As expected from our biochemical data, the G140S-Q148H mutant caused a large increase in the EC50 values for RAL and XZ-259 to 1.7 and 6.8 muM, respectively (Table 1).
Result: However, both conformations predicted modest (2- to 8-fold) increases in IC50 against the Y143R and N155H mutants and a greater increase (15- to 225-fold) against the G140S
Factors associated with virological success with raltegravir-containing regimens and prevalence of raltegravir-resistance-associated mutations at failure in the ARCA database.
PMID: 23289841
2013
Clinical microbiology and infection
Abstract: Mutations associated with RAL failure were detected in 12/24 subjects with an integrase genotype, with the prevalence of Q148H + G140S.
Impact of primary elvitegravir resistance-associated mutations in HIV-1 integrase on drug susceptibility and viral replication fitness.
PMID: 23529738
2013
Antimicrobial agents and chemotherapy
Abstra
Abstract: Less commonly observed primary IN mutations also showed a range of reduced EVG susceptibilities: 40- to 94-fold for T66K and Q148K and 5- to 10-fold for T66A, E92G, and Q148H.
Abstract: Primary INSTI resistance-associated mutations (RAMs) at six IN positions have been identified in HIV-1-infected patients failing EVG-containing regimens in clinical studies: T66I/A/K, E92Q/G, T97A, S147G, Q148R/H/K, and N155H.
Natural polymorphisms of HIV-1 subtype-C integrase coding region in a large group of ARV-naive infected individuals.
Abstract: A major drug resistance mutation for raltegravir (RAL) and elvitegravir (EVG), Q148H, was retrieved from one patient and another RAL primary resistance mutation, Y143H, was also retrieved from another patient.
HIV mutation literature information.
PMID: 
2014
PloS one
Browser Board
Co-occurred Entities
Filtrator
ViMRT